<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129442">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911676</url>
  </required_header>
  <id_info>
    <org_study_id>1303011716</org_study_id>
    <nct_id>NCT01911676</nct_id>
  </id_info>
  <brief_title>Translational Neuroscience Optimization of GlyT1 Inhibitor</brief_title>
  <acronym>NCATS</acronym>
  <official_title>Translational Neuroscience Optimization of GlyT1 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves an interlinked design to determine the dose associated with optimal
      activity and occupancy of the Glyt1I  PF-03463275 in healthy subjects and schizophrenia
      subjects and to test this dose in combination with cognitive remediation in the treatment of
      cognitive impairments of Schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Receptor Occupancy after administration of PF-03463275  using PET.</measure>
    <time_frame>Change from Baseline in Receptor Occupancy at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To  examine the receptor occupancy associated with PF-03463275.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration in  Pre-Frontal Cortex function with PF-03463275</measure>
    <time_frame>Change from Baseline in Pre-frontal Cortex Function at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To test whether PF-03463275 alters Pre-Frontal Cortex function during a working memory task in a dose-related manner, as measured with fMRI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy of PF03463275 on cognitive measures in Schizophrenic subjects.</measure>
    <time_frame>Change from Baseline in cognitive measures at 5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To test the efficacy of PF03463275 on Cognitive Test Performance in subjects with Schizophrenia</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cognitive Impairments Associated With Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PF-03463275 Active Dose#1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Dose between 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-03463275 Active Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active dose between 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-03463275 Active Dose #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active dose between 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo- no active dose of PF-03463275.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03463275</intervention_name>
    <arm_group_label>PF-03463275 Active Dose#1</arm_group_label>
    <arm_group_label>PF-03463275 Active Dose #2</arm_group_label>
    <arm_group_label>PF-03463275 Active Dose #3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Males or females 21 to 55 years of age (inclusive).

          -  3) Able to provide written informed consent.

          -  4) Only CYP2D6 extensive metabolizers.

        Exclusion Criteria:

          -  1) No ongoing acute medical issues

          -  2) Clinically significant ECG abnormality

          -  3) Blood donation within eight weeks of the start of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak C D'Souza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle K Carbuto, BA</last_name>
    <phone>(203) 376-3850</phone>
    <email>michelle.carbuto@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Carbuto, BA</last_name>
      <phone>203-376-3850</phone>
      <email>michelle.carbuto@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Deepak C D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
